Dateline City:
WALTHAM, Mass., and KENILWORTH, N.J.
Clinical Trial Will Evaluate TESAROs PARP Inhibitor with Mercks Anti-PD-1 Therapy in Patients with Breast and Ovarian Cancers
WALTHAM, Mass., and KENILWORTH, N.J., May 30, 2015 TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a collaboration to evaluate the combination of TESAROs niraparib plus Mercks anti-PD1 therapy, KEYTRUDA (pembrolizumab), in a Phase 1/2 clinical trial.
Language:
English
read more